BCL2 and acute myeloid leukemia: More significantly, P1D-34 in combination with Bcl-2 inhibitor ABT-199 displayed notable synergistic anti-proliferative activities in ABT-199-resistant AML cell lines, further highlighting the potential therapeutic value of targeted Pin1 degradation.